Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Study Phase : Discovery Platform
Sponsor : Alnylam Pharmaceuticals
Deal Size : $2,200.0 million
Deal Type : Collaboration
Alnylam and PeptiDream Enter into Collaboration Agreement
Details : PeptiDream will select, optimize, and synthesize peptides for each receptor. Alnylam will then generate peptide-siRNA conjugates and perform in vitro and in vivo studies to support final peptide selection.
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Undisclosed
July 29, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Highest Development Status : Discovery Platform
Sponsor : Alnylam Pharmaceuticals
Deal Size : $2,200.0 million
Deal Type : Collaboration